ATAD3A and metabolic dysfunction-associated steatotic liver disease: Our data suggests that ATAD3A is pivotal for the PINK1-Parkin–mediated mitophagy and loss of ATAD3A almost halted the mitophagy, making it a promising therapeutic target for NAFLD.